

# PAXCESS™

Patient Support Program

## For patients prescribed PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets), the PAXCESS™ Patient Support Program offers the following:

- Insurance benefits verification
- Ability to enroll online
- Live PAXCESS representatives who can provide information about insurance benefits and program eligibility
- Help with identifying financial assistance resources, including:

Co-Pay Savings Program\*



for eligible, commercially insured patients

US Government Patient Assistance Program (USG PAP)†



operated by Pfizer for Medicare and Medicaid, and uninsured patients beginning on December 1, 2023

### Need assistance?



**CALL TOLL-FREE**

1-877-C19-PACK (1-877-219-7225)

Mon-Fri 9AM-9PM ET  
Sat-Sun 9AM-5PM ET



**VISIT**

[PAXLOVID.com](https://www.paxlovid.com)

Please see Full Prescribing Information, including **BOXED WARNING** and Patient Information, [here](https://www.paxlovid.com) or at [PAXLOVID.com](https://www.paxlovid.com).

\*Terms and Conditions apply. Please see full terms and conditions at [PAXLOVID.com/PAXCESS-terms-and-conditions](https://www.paxlovid.com/PAXCESS-terms-and-conditions).

†With a focus on ensuring affordable access for patients, the USG Patient Assistance Program operated by Pfizer will continue to provide patients on Medicare, Medicaid, Tricare, VA Community Care Network, and those who are uninsured access to PAXLOVID for free through December 31, 2024. PAXLOVID, through the USG PAP, is not available to patients who have commercial prescription drug health insurance. The USG PAP operated by Pfizer is an independent program with separate eligibility requirements offered by the United States Department of Health and Human Services and is not owned by Pfizer.



**Paxlovid™**  
(nirmatrelvir 150 mg tablets | ritonavir 100 mg tablets)